

William Weiss, MS
UNT System College of Pharmacy
Pharmaceutical Sciences
Email: William.Weiss@unthsc.edu



Area of Expertise

Pre-Clinical Services evaluate new therapies against infections using animal models. These studies are done in collaboration with pharmaceutical and academic researchers, and several of these therapies are now being used clinically to treat patients.

Qualifications

MS in Biology, Fairleigh Dickinson University
BS in Microbiology, Rutgers University

Recent Publications

Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- And Metallo- β -lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections

Liu, B., Trout, R. E. L., Chu, G. H., McGarry, D., Jackson, R. W., Hamrick, J. C., Daigle, D. M., Cusick, S. M., Pozzi, C., De Luca, F., Benvenuti, M., Mangani, S., Docquier, J. D., Weiss, W. J., Pevear, D. C., Xerri, L. & Burns, C. J., 26 Mar 2020, In : Journal of Medicinal Chemistry. 63, 6, p. 2789-2801 13 p.

C1-CBP-vancomycin: Impact of a Vancomycin C-Terminus Trimethylammonium Cation on Pharmacological Properties and Insights into Its Newly Introduced Mechanism of Action

Wu, Z. C., Isley, N. A., Okano, A., Weiss, W. J. & Boger, D. L., 7 Feb 2020, In : Journal of Organic Chemistry. 85, 3, p. 1365-1375 11 p.

DAV131A Protects Hamsters from Lethal Clostridioides difficile Infection Induced by Fluoroquinolones

Saint-Lu, N., Burdet, C., Sablier-Gallis, F., Corbel, T., Nevière, A., Sayah-Jeanne, S., Pulse, M., Weiss, W., Ferreira, S., Andremont, A., Mentré, F. & de Gunzburg, J., 2020, In : Antimicrobial agents and chemotherapy. 64, 1, e01196-19.

Liposomal mupirocin holds promise for systemic treatment of invasive Staphylococcus aureus infections

Goldmann, O., Cern, A., Muesken, M., Rohde, M., Weiss, W., Barenholz, Y. & Medina, E., 28 Dec 2019, In : Journal of Controlled Release. 316, p. 292-301 10 p.

In Vivo Efficacy of Novel Monobactam LYS228 in Murine Models of Carbapenemase-Producing Klebsiella pneumoniae Infection

Weiss, W. J., Pulse, M. E., Nguyen, P. & Growcott, E. J., Apr 2019, In : Antimicrobial agents and chemotherapy. 63, 4, e02214-18.

Pharmacological, toxicological, and dose range assessment of OG716, a novel lantibiotic for the treatment of clostridium difficile-associated infection

Pulse, M. E., Weiss, W. J., Kers, J. A., DeFusco, A. W., Park, J. H. & Handfield, M., Apr 2019, In : Antimicrobial agents and chemotherapy. 63, 4, e01904-18.

Treatment and prevention of recurrent Clostridium difficile infection with functionalized bovine antibody-enriched whey in a hamster primary infection model

Heidebrecht, H. J., Weiss, W. J., Pulse, M., Lange, A., Gisch, K., Kliem, H., Mann, S., Pfaffl, M. W., Kulozik, U. & von Eichel-Streiber, C., Feb 2019, In : Toxins. 11, 2, 98.

Antibiotic-induced dysbiosis predicts mortality in an animal model of clostridium difficile infection

Burdet, C., Sayah-Jeanne, S., Nguyen, T. T., Hugon, P., Sablier-Gallis, F., Saint-Lu, N., Corbel, T., Ferreira, S., Pulse, M., Weiss, W., Andremont, A., Mentré, F. & De Gunzburg, J., Oct 2018, In : Antimicrobial agents and chemotherapy. 62, 10,

e00925.

OG716: Designing a fit-for-purpose lantibiotic for the treatment of Clostridium difficile infections

Kers, J. A., DeFusco, A. W., Park, J. H., Xu, J., Pulse, M. E., Weiss, W. J. & Handfield, M., Jun 2018, In : PLoS ONE. 13, 6, e0197467.

Mutacin 1140 lantibiotic variants are efficacious against Clostridium difficile infection

Kers, J. A., Sharp, R. E., Defusco, A. W., Park, J. H., Xu, J., Pulse, M. E., Weiss, W. J. & Handfield, M., 16 Mar 2018, In : Frontiers in Microbiology. 9, MAR, 415.